Cefotaxime vs Nafcillin and Tobramycin for the Treatment of Serious Infection: Comparative Cost-effectiveness

Richard D. Moore, Craig R. Smith, James J. Holloway, Paul S. Lietman

Research output: Contribution to journalArticle

Abstract

• To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550±$1,740 for cefotaxime and $3,160±$1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980±$1,800 for cefotaxime and $4,170±$1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.

Original languageEnglish (US)
Pages (from-to)1153-1157
Number of pages5
JournalArchives of internal medicine
Volume146
Issue number6
DOIs
StatePublished - Jun 1986

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Cefotaxime vs Nafcillin and Tobramycin for the Treatment of Serious Infection: Comparative Cost-effectiveness'. Together they form a unique fingerprint.

  • Cite this